Skip to main content
main-content

ADA 2019

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

American Diabetes Association 79th Scientific Sessions coverage

Including news and expert commentaries on the CAROLINA trial, REWIND trial, and PIONEER trial (June 7–11).

Conference overview

The 2019 American Diabetes Association Scientific Sessions (ADA 2019) draws on the latest research and clinical guidance, and encompasses a variety of themes, including:

Conference coverage

You can keep up to date in a number of ways:

View recommended sessions from our Editorial Board below.

Featured

Expert interviews

13-06-2019 | Prediabetes | ADA 2019 | Article

Expert commentary: The RISE study

With all three RISE studies now published, John Wilding reflects on the pathophysiological differences between children and adults with type 2 diabetes (2:12).

13-06-2019 | Physical activity | ADA 2019 | Article

Expert highlights: High performance exercise and type 1 diabetes

John Wilding talks about research presented at the ADA Scientific Sessions looking at the management of type 1 diabetes in elite athletes (3:18).

13-06-2019 | Insulin degludec/Liraglutide | ADA 2019 | Article

Expert commentary: The DUAL VIII trial

Sanjay Kalra discusses the implications of the DUAL VIII trial, which looked at the effect of IDegLira versus glargine on the time to treatment intensification in people with type 2 diabetes (2:39).

12-06-2019 | Linagliptin | ADA 2019 | Article

Expert commentary: An endocrinologist's view of the CAROLINA trial

Sanjay Kalra tells us why he is so reassured by the findings of the CAROLINA trial pitting linagliptin against glimepiride (2:38).

12-06-2019 | Linagliptin | ADA 2019 | Article

Clinical takeaway: The CAROLINA trial

John Wilding outlines the key take-home message from the CAROLINA trial comparing the cardiovascular risk profile of the dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride (0:37).

11-06-2019 | Semaglutide | ADA 2019 | Article

Researcher comment: The PIONEER 6 oral semaglutide cardiovascular outcomes study

PIONEER 6 lead investigator Mansoor Husain discusses the results of the trial, and how oral and injectable semaglutide compare and can be used in the clinic (4:40).

10-06-2019 | ADA 2019 | Article

Expert highlights: ADA session “Making a difference in 5 minutes”

Lori Berard gives an overview of the ADA session “Making a difference in five minutes: Interventions in diabetes for anyone.” (2:0)

10-06-2019 | Hypoglycemia | ADA 2019 | Article

Expert highlights: Novel insulins and insights into hypoglycemia from continuous glucose monitoring

Stephanie Amiel overviews her ADA highlights, including novel rapid-acting insulins and the sometimes surprising insights that technology offers into hypoglycemia (3:20).

10-06-2019 | Dulaglutide | ADA 2019 | Article

Expert commentary: A nurse educator’s view of the REWIND trial

Nurse educator Lori Berard gives her view of how the REWIND trial can help clinicians working with people with type 2 diabetes (1:48).

10-06-2019 | Dulaglutide | ADA 2019 | Article

Expert commentary: The REWIND trial

John Wilding discusses how the results of the REWIND study add to our knowledge of the effects of the glucagon-like peptide-1 receptor agonist class in people with varying degrees of cardiovascular risk (3:37).

10-06-2019 | Dulaglutide | ADA 2019 | Article

Expert commentary: A primary care view of the REWIND trial

Kamlesh Khunti discusses what the REWIND findings mean for doctors working with people with type 2 diabetes and high cardiovascular risk in primary care (1:43).

07-06-2019 | Prediabetes | ADA 2019 | Article

Expert commentary: The D2d trial

Kim Pfotenhauer considers whether the D2d trial has settled the question of the role of vitamin D in the prevention of type 2 diabetes (1:53).

Research news

13-06-2019 | Dapagliflozin | ADA 2019 | News

Dapagliflozin renoprotective in diabetes patients with preserved kidney function

Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.

12-06-2019 | Canagliflozin | ADA 2019 | News

Canagliflozin benefits span multiple cardiovascular backgrounds

Canagliflozin reduces the risk for major cardiovascular events and kidney failure versus placebo in patients with type 2 diabetes and chronic kidney disease with and without a known history of cardiovascular disease, CREDENCE study data show.

12-06-2019 | DPP-4 inhibitors | ADA 2019 | News

CARMELINA findings confirmed in highest CV risk subgroups

Secondary data from the CARMELINA trial, presented at the 79th ADA Scientific Sessions in San Francisco, California, USA, confirm the positive primary cardiovascular and renal safety findings, this time in particularly high-risk patients.

ADA 2019 pre-conference

Key clinical trials at ADA 2019

Get up to speed on the clinical trials headlining ADA 2019 with our brief overviews.

Session recommendations

The Medicine Matters diabetes Editorial Board share their symposia picks ahead of ADA 2019.

Image Credits